Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Influence of Metformin on Igf-1 Levels in Humans: A Systematic Review and Meta-Analysis Publisher Pubmed



Yang X1 ; Kordvarkaneh H2 ; Talaei S3 ; Clark CCT4 ; Zanghelini F5 ; Tan SC6 ; Zarezadeh M7 ; Mousavi SM8 ; Rahmani J8 ; Zhang Y9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of General Medicine, Zhumadian Central Hospital, Zhumadian, 463000, He'nan, China
  2. 2. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry, CV15FB, United Kingdom
  5. 5. National Institute for Health Research (NIHR) Innovation Observatory, Newcastle University, Newcastle Upon Tyne, United Kingdom
  6. 6. UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
  7. 7. Department of Nutrition, Students’ Research Committee, Nutrition Research Center, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
  8. 8. Department of Community Nutrition, Students’ Scientific Research Center (SSRC), School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran
  9. 9. School of Public Health and Health Management, Chongqing Medical University, Chongqing, 400016, China

Source: Pharmacological Research Published:2020


Abstract

Background: A meta-analysis is needed to comprehensively consolidate findings from the influence of metformin on IGF-1 levels. The present study was conducted with the objective to accurately evaluate the influence of metformin intake on IGF-1 levels via a meta-analysis of randomized controlled trials. Methods: A comprehensive systematic search was carried out in PubMed/MEDLINE, Web of Science, SCOPUS and Embase from inception until June 2019. Weighted mean difference (WMD) with the 95 % CI were applied for estimating the effects of metformin on serum IGF-1 levels. Results: 11 studies involving a total of 569 individuals reported changes in IGF-1 plasma concentrations as an outcome measure. Pooled results demonstrated an overall non-significant decline in IGF-1 following metformin intake (WMD: -8.292 ng/ml, 95 % CI: -20.248, 3.664, p = 0.174) with heterogeneity among (p = 0.000,I2 = 87.1 %). The subgroup analyses displayed that intervention duration <12 weeks on children (WMD:-55.402 ng/ml, 95 % CI: -79.845, -30.960, I2 = 0.0 %) significantly reduced IGF-1. Moreover, in age 18 < years older metformin intake (WMD: 15.125 ng/ml, 95 % CI: 5.522, 24.729, I2 = 92.5 %) significantly increased IGF-1 than 18 ≤ years older (WMD:-1.038 ng/ml, 95 % CI: -3.578,1.502,I2 = 78.0 %). Following dose-response evaluation, metformin intake reduced IGF-1 (coefficient for dose-response analysis= -13.14, P = 0.041 and coefficient for liner analysis= -0.066, P = 0.038) significantly based on treatment duration. Conclusion: We found in children, intervention duration <12 weeks yielded significant reductions in IGF-1, whilst paradoxically, in participants >18 years old, metformin intake significantly increased IGF-1. We suggest that caution be taken when interpreting the findings of this review, particularly given the discordant supplementation practices between children and adults. © 2019 Elsevier Ltd